- In April 2023, Moderna, Inc. announced the initiation of a Phase 3 clinical trial for its mRNA-based influenza vaccine, aiming to provide broader and more adaptive seasonal flu protection. This development underscores Moderna’s strategic expansion beyond COVID-19 into a wider mRNA vaccine portfolio, highlighting the growing importance of platform technologies for rapid vaccine development and improved efficacy in combating evolving viral strains
- In March 2023, GlaxoSmithKline (GSK) and CureVac AG formed a strategic collaboration to co-develop next-generation mRNA vaccines targeting respiratory viruses, including influenza and respiratory syncytial virus (RSV). This partnership emphasizes the accelerating convergence of biotech and pharma to leverage mRNA platforms for more durable, scalable immunization solutions, particularly suited to seasonal and emerging respiratory threats
- In March 2023, Bharat Biotech received approval for the intranasal COVID-19 vaccine iNCOVACC as a booster dose in India. This development marks a significant milestone in non-invasive vaccine delivery, potentially improving compliance and ease of administration, particularly in large-scale immunization programs across resource-limited settings
- In February 2023, Pfizer announced expanded trials of its pentavalent meningococcal conjugate vaccine (MenABCWY), which aims to protect against five common meningococcal serogroups. This move reflects growing market focus on combination vaccines that offer broader coverage, fewer doses, and improved adherence across target populations, especially adolescents and young adults
- In January 2023, Sanofi launched a global initiative to expand access to its hexavalent pediatric vaccine, Hexaxim, in emerging markets through Gavi support. This development demonstrates the company’s commitment to vaccine equity, as well as the rising demand for combination pediatric vaccines in low- and middle-income countries. It also reinforces public-private collaboration efforts in strengthening immunization programs globally
